Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, researchers reported at the ...

Even when diagnosed early, triple-negative breast cancer (TNBC) has a higher mortality rate compared with other breast cancer ...

Hopes of a bright new future in stroke risk management in AF were dashed when asundexian failed against apixaban in the ...

Shares of Bristol Myers Squibb Co. BMY slid 1.00% to $58.12 Tuesday, on what proved to be an all-around grim trading session ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with ...

Bristol-Myers Squibb Co. plotted to rip off investors in a 2016 acquisition through legal gamesmanship aimed at evading a ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.IM06wodO.js ...

Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven ...

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that a poster for BL-B01D1, a ...

Lotte Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO) established in 2022, is ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, researchers reported at the American Society of Hematology meeting in San Diego.